Sibrafiban

Sibrafiban (RO 48-3657) is the orally active, nonpeptide, double-proagent of Ro 44-3888 and a selective glycoprotein IIb/IIIa receptor antagonist. Sibrafiban inhibits platelet aggregation[1][2][3].

Product Specifications

CAS Number

[172927-65-0]

Product Name Alternative

RO 48-3657

UNSPSC

12352005

Target

Integrin

Type

Reference compound

Related Pathways

Cytoskeleton

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/sibrafiban.html

Purity

99.67

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(OCC)COC1CCN(C([C@@H](NC(C2=CC=C(/C(N)=N/O)C=C2)=O)C)=O)CC1

Molecular Formula

C20H28N4O6

Molecular Weight

420.47

References & Citations

[1]M Dooley, et al. Sibrafiban. Drugs. 1999 Feb;57 (2) :225-30; discussion 231-2.|[2]B Wittke, et al. Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with ticlopidine and aspirin. Br J Clin Pharmacol. 2000 Mar;49 (3) :231-9.|[3]Jeffrey T Billheimer, et al. Effects of glycoprotein IIb/IIIa antagonists on platelet activation: development of a transfer method to mimic peak to trough receptor occupancy. Thromb Res. 2002 Sep 15;107 (6) :303-17.